Research programme: ulcerative colitis therapeutics - Warner Chilcott
Latest Information Update: 18 Dec 2013
Price :
$50 *
At a glance
- Originator Warner Chilcott
- Developer Actavis Inc
- Class Aminosalicylic acids; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 18 Dec 2013 No development reported - Preclinical for Ulcerative colitis in USA (unspecified route)
- 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc